Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 16/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 6/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860613 | 0.89 | PPARD (0.49) | PPARDPPARGPPARAPTGDR2SMN1; SMN2 | |
| SCHEMBL5860755 | 0.87 | PTGDR2 (0.48) | PPARDPPARGPPARAPTGDR2SMN1; SMN2 | |
| SCHEMBL5861011 | 0.86 | PPARD (0.53) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL5861000 | 0.83 | PPARD (0.54) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL5862790 | 0.81 | PPARD (0.46) | PPARDPPARGPPARAPTGDR2SMN1; SMN2 | |
| SCHEMBL6164628 | 0.80 | PPARD (0.47) | PPARDPPARGPPARAPTGDR2SMN1; SMN2 | |
| SCHEMBL5862807 | 0.77 | SMN1; SMN2 (0.50) | PPARDPPARGPPARAPTGDR2SMN1; SMN2 | |
| SCHEMBL5860763 | 0.76 | SMN1; SMN2 (0.42) | PPARDPPARGPPARAPTGDR2SMN1; SMN2 | |
| SCHEMBL5860804 | 0.73 | PPARD (0.53) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL5861174 | 0.72 | SMN1; SMN2 (0.44) | PPARDPPARGPPARAPTGDR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091237-B2 | Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | PPARG, PPARD, PPARA | PPARD 2/4885PPARG 1/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.